Compile Data Set for Download or QSAR
Report error Found 262 Enz. Inhib. hit(s) with all data for entry = 2934
TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385676BDBM385676(4-{5- [(cyclopropylmethyl) amino]-[1,2,4] triazolo...)
Affinity DataIC50: 5nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385711BDBM385711(4-(7-{[(4- fluorophenyl) methyl]amino}- [1,2,4]tri...)
Affinity DataIC50: 5nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385701BDBM385701(4-{7-[(oxetan-3- ylmethyl)amino]- [1,2,4]triazolo[...)
Affinity DataIC50: 5nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385707BDBM385707(4-(7-{[2- (dimethylamino) ethyl]amino}- [1,2,4]tri...)
Affinity DataIC50: 8nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239931BDBM50239931(CHEMBL4067995 | US10287286, Example 142)
Affinity DataIC50: 8nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385693BDBM385693(4-{7- [(cyclopropyl- methyl) amino]- [1,2,4]triazo...)
Affinity DataIC50: 9nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385702BDBM385702(4-{7-[(3,3,3- trifluoropropyl) amino]- [1,2,4]tria...)
Affinity DataIC50: 9nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239883BDBM50239883(CHEMBL4090769 | US10287286, Example 5)
Affinity DataIC50: 10nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385700BDBM385700(4-{7-[(2,2- difluoroethyl) amino]- [1,2,4]triazolo...)
Affinity DataIC50: 10nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385674BDBM385674(4-[5- (dimethylamino)- [1,2,4]triazolo[1,5- a]pyri...)
Affinity DataIC50: 11nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385747BDBM385747(US10287286, Example 150)
Affinity DataIC50: 12nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239889BDBM50239889(CHEMBL4072842 | US10287286, Example 100)
Affinity DataIC50: 13nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385709BDBM385709(4-(7-{[(2- fluorophenyl) methyl]amino}- [1,2,4]tri...)
Affinity DataIC50: 13nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385792BDBM385792(cyclopropylmethyl N-[5-(4- cyano-3-fluorophenyl)- ...)
Affinity DataIC50: 14nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385853BDBM385853(US10287286, Example 251)
Affinity DataIC50: 17nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385706BDBM385706(4-{7-[(oxolan-2- ylmethyl)amino]- [1,2,4]triazolo[...)
Affinity DataIC50: 20nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385809BDBM385809(US10287286, Example 211)
Affinity DataIC50: 25nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239888BDBM50239888(CHEMBL4094292 | US10287286, Example 103)
Affinity DataIC50: 25nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385698BDBM385698(4-{7-[(oxolan-3- ylmethyl)amino]- [1,2,4]triazolo[...)
Affinity DataIC50: 25nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385742BDBM385742(US10287286, Example 146)
Affinity DataIC50: 27nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385851BDBM385851(US10287286, Example 249)
Affinity DataIC50: 27nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385750BDBM385750(N-[5-(4-cyano-3- fluorophenyl)- [1,2,4]triazolo[1,...)
Affinity DataIC50: 28nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385710BDBM385710(4-(7-{[(3- fluorophenyl) methyl]amino}- [1,2,4]tri...)
Affinity DataIC50: 29nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 386909BDBM386909(US10287286, Example 260)
Affinity DataIC50: 29nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385680BDBM385680(4-(5-{[3- (dimethylamino) propyl]amino}- [1,2,4]tr...)
Affinity DataIC50: 29nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385820BDBM385820(US10287286, Example 219)
Affinity DataIC50: 30nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385688BDBM385688(4-[5- (cyclopropylamino)- [1,2,4]triazolo[1,5- a]p...)
Affinity DataIC50: 32nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385708BDBM385708(4-[7-(benzylamino)- [1,2,4]triazolo[1,5- a]pyridin...)
Affinity DataIC50: 33nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239937BDBM50239937(CHEMBL4083851 | US10287286, Example 3)
Affinity DataIC50: 34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239915BDBM50239915(CHEMBL4067559 | US10287286, Example 6)
Affinity DataIC50: 34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385694BDBM385694(4-{7-(2- methoxyethyl) amino}- [1,2,4]triazolo[1,5...)
Affinity DataIC50: 34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385771BDBM385771(N-[5-(4-cyano-3- fluorophenyl)- [1,2,4]triazolo[1,...)
Affinity DataIC50: 34nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385850BDBM385850(US10287286, Example 248)
Affinity DataIC50: 35nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385808BDBM385808(US10287286, Example 210)
Affinity DataIC50: 36nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385697BDBM385697(4-{7-[(oxan-4- ylmethyl)amino]- [1,2,4]triazolo[1,...)
Affinity DataIC50: 37nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239890BDBM50239890(CHEMBL4095005 | US10287286, Example 4)
Affinity DataIC50: 39nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385773BDBM385773(US10287286, Example 176)
Affinity DataIC50: 40nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385749BDBM385749(N-[5-(4- cyanophenyl)- [1,2,4]triazolo[1,5- a]pyri...)
Affinity DataIC50: 42nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385748BDBM385748(N-[5-(4- cyanophenyl)- [1,2,4]triazolo[1,5- a]pyri...)
Affinity DataIC50: 47nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385722BDBM385722(2-fluoro-4-(7-{[(3- methyloxetan-3- yl)methyl]amin...)
Affinity DataIC50: 47nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385713BDBM385713(4-[7-(benzyloxy)- [1,2,4]triazolo[1,5- a]pyridin-5...)
Affinity DataIC50: 49nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385719BDBM385719(tert-butyl N-[5-(4- cyano-3- fluorophenyl)- [1,2,4...)
Affinity DataIC50: 49nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385766BDBM385766(N-[5-(4-cyano-3- fluorophenyl)- [1,2,4]triazolo[1,...)
Affinity DataIC50: 49nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239921BDBM50239921(CHEMBL4075128 | US10287286, Example 7)
Affinity DataIC50: 50nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385714BDBM385714(tert-butyl N-[5-(4- cyanophenyl)- [1,2,4]triazolo[...)
Affinity DataIC50: 52nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239913BDBM50239913(CHEMBL4102714 | US10287286, Example 223)
Affinity DataIC50: 52nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385794BDBM385794(1-methylpiperidin-4-yl N-[5- (4-cyano-3 -fluorophe...)
Affinity DataIC50: 53nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385721BDBM385721(2-fluoro-4-{7- [(3,3,3- trifluoropropyl)- amino][1...)
Affinity DataIC50: 53nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 50239898BDBM50239898(CHEMBL4070540 | US10287286, Example 2)
Affinity DataIC50: 54nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 385712BDBM385712(4-[7- (cyclopropyl- methoxy)- [1,2,4]triazolo[1,5-...)
Affinity DataIC50: 54nMAssay Description:The IC50 values for the PHD1 enzyme (residues 1-407) were determined by mixing increasing amounts of a compound of the invention with a fixed amount ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/29/2020
Entry Details
US Patent

Displayed 1 to 50 (of 262 total ) | Next | Last >>
Jump to: